GLP-3RT
Price range: $130.00 through $165.00
For research use only. Retatrutide is a synthetic triple-incretin peptide acting as a co-agonist at GLP-1, GIP, and glucagon receptors, supplied for advanced laboratory research into multi-receptor metabolic signaling and energy regulation pathways.
| FORM | PURITY |
|---|---|
| Lyophilized Powder | ≥99% (HPLC) |
GLP-3RT For Laboratory Research
For In Vitro Research Use Only – Not for Human or Veterinary Application
Retatrutide (GLP3-RT) is a synthetic peptide engineered as a triple agonist at three distinct G protein-coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This tri-receptor activity distinguishes it from dual-agonist compounds and positions it as a research tool for studying the complex crosstalk between incretin and glucagon signaling networks.
Laboratory research interest centers on Retatrutide’s ability to simultaneously activate divergent metabolic pathways — GLP-1R and GIPR stimulation is associated with insulinotropic and anorexigenic signaling, while GCGR activation drives hepatic glucose output and thermogenesis via distinct cAMP-mediated cascades. Researchers studying receptor pharmacology, downstream signal transduction, and multi-agonist peptide design will find Retatrutide a relevant compound for examining how combinatorial receptor engagement influences metabolic homeostasis in controlled in vitro and ex vivo models.
Available in 20mg and 30mg vials. Tested in the USA for research and educational use.
Compound Details
| Full Name | GLP Receptor Analog (Research Compound) |
| Receptor Target | GLP Receptor |
| Vial Size | 20 mg / vial |
| Purity | ≥99% by HPLC |
| Appearance | White lyophilized powder |
| Solubility | Sterile bacteriostatic water |
| Storage | −20°C long-term; 4°C short-term (≤4 weeks lyophilized) |
| For Use | Laboratory and in vitro research purposes only |
Public Research References
Published Research References
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409–1439. PMID: 17928588 →
- Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525–536. PubMed →
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756. PMID: 29617641 →
- Forzano I, et al. The Agonists of GLP-1 Receptor: Walking Down Therapeutic Trails in Cardiometabolic Disease. JACC Basic Transl Sci. 2022;7(9):929–943. PubMed →
All references are provided for informational purposes. Products are for laboratory and scientific research purposes only. Not for human or animal consumption.
RESEARCH USE ONLY
All products sold by Hive Mind Peptides are intended strictly for laboratory and scientific research purposes only. These materials are not approved by the FDA and are not intended for human or veterinary use, clinical applications, diagnostic procedures, or therapeutic treatment of any kind. You must be 21 years of age or older to purchase.
By purchasing from Hive Mind Peptides, you confirm that you are a qualified researcher and that all materials will be handled solely within an appropriate research environment by personnel who understand the risks, limitations, and regulatory requirements associated with investigational compounds. Products must not be administered to humans or animals, represented as therapeutic agents, or used for any medical purpose.
Use of these materials is entirely at your own risk. Hive Mind Peptides assumes no liability for misuse, unsafe handling, improper application, or any regulatory or compliance issues arising from their use.
